Featured Articles

  1. Psychiatric Drug Development Renaissance: With Familiar Risks 1/6/2026

    Emerging psychiatric therapies bring hope, but progress is fragile. Biomarker-driven, mechanism-first approaches help overcome biological, regulatory, and commercial barriers.

  2. Trailblazing Clinical Drug Development In Dermatology 1/6/2026

    AI, imaging, and biomarkers are transforming trials, reducing subjectivity and improving sensitivity while enabling decentralized designs, faster timelines, and more precise insights.

  3. Year-In-Review: Clinical Research Today And Tomorrow 12/10/2025

    As the industry prepares for 2026, sponsors and investors alike face a pivotal moment — one that demands a more deliberate, insight-driven approach to early clinical development.

  4. The Impact Of Expert PK/PD Modeling In Psychedelic Research 12/2/2025

    Model-informed development that integrates preclinical and literature-based data is enabling smarter predictions of exposure and safety, transforming psychedelic research and advancing clinical innovation.

  5. The Evolving Role Of Healthy Participants In Early Immuno-Oncology Trials 11/21/2025

    Explore how leveraging healthy participants, advanced immune-challenge models, and high-dimensional biomarker analyses can transform early immuno-oncology development.

  6. Bridging The Trust Gap: How Patient Advocacy Groups Transforms Trial Recruitment 10/27/2025

    Explore how collaboration between researchers and Patient Advocacy Groups (PAGs) can bridge the trust gap that undermines recruitment and can make trial participation more approachable and meaningful.

  7. The Immunotherapy Revolution's Path To Precision 10/27/2025

    Learn how comprehensive immune profiling and translational models can illuminate these mechanisms, inform dose selection, and guide the next generation of immunotherapies toward safer, more targeted innovation.

  8. Best Practices For Evaluating Immunologically Active Compounds 10/9/2025

    Gain insight into the evolving landscape of immune-based drug development and best practices CROs should adopt to overcome its unique challenges.

  9. Early Immune Profiling With In Vivo, In Vitro, And Ex Vivo Systems 10/7/2025

    Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.

  10. What Do Cancer Patients Really Want From mHealth Technology? 9/30/2025

    The success of mobile health (mHealth) tools depends on whether patients want to use them. Patient perspectives can guide design to reduce burden, build trust, and make digital tools truly meaningful.